JPH10500485A - サイトカインモジュレーターのスクリーニング - Google Patents

サイトカインモジュレーターのスクリーニング

Info

Publication number: JPH10500485A
Authority: JP; Japan
Prior art keywords: receptor; promoter; protein; rel; cells
Prior art date: 1994-05-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP7529916A

Other languages

English (en)

Japanese (ja)

Inventor

ヘルマン，トーマス

パイク，ジョン・ダブリュー

Original Assignee

リガンド・ファーマシューティカルズ・インコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-18

Filing date

1995-05-15

Publication date

1998-01-13

1995-05-15 Application filed by リガンド・ファーマシューティカルズ・インコーポレイテッド filed Critical リガンド・ファーマシューティカルズ・インコーポレイテッド

1998-01-13 Publication of JPH10500485A publication Critical patent/JPH10500485A/ja

Status Pending legal-status Critical Current

Links

108090000695 Cytokines Proteins 0.000 title claims abstract description 64
102000004127 Cytokines Human genes 0.000 title claims abstract description 62
238000012216 screening Methods 0.000 title claims abstract description 15
108090000623 proteins and genes Proteins 0.000 claims abstract description 127
102000004169 proteins and genes Human genes 0.000 claims abstract description 102
238000009739 binding Methods 0.000 claims abstract description 71
230000027455 binding Effects 0.000 claims abstract description 69
108010038795 estrogen receptors Proteins 0.000 claims abstract description 49
238000000034 method Methods 0.000 claims abstract description 49
239000003814 drug Substances 0.000 claims abstract description 38
229940079593 drug Drugs 0.000 claims abstract description 31
102000027411 intracellular receptors Human genes 0.000 claims abstract description 22
108091008582 intracellular receptors Proteins 0.000 claims abstract description 22
108020003175 receptors Proteins 0.000 claims abstract description 20
102000005962 receptors Human genes 0.000 claims abstract description 19
206010061218 Inflammation Diseases 0.000 claims abstract description 9
230000004054 inflammatory process Effects 0.000 claims abstract description 9
230000001575 pathological effect Effects 0.000 claims abstract description 8
206010040070 Septic Shock Diseases 0.000 claims abstract description 5
108090000468 progesterone receptors Proteins 0.000 claims abstract description 5
230000036303 septic shock Effects 0.000 claims abstract description 5
208000007766 Kaposi sarcoma Diseases 0.000 claims abstract description 4
208000034578 Multiple myelomas Diseases 0.000 claims abstract description 4
208000001132 Osteoporosis Diseases 0.000 claims abstract description 4
206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 4
201000004681 Psoriasis Diseases 0.000 claims abstract description 4
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 4
102000034527 Retinoid X Receptors Human genes 0.000 claims abstract description 3
108010038912 Retinoid X Receptors Proteins 0.000 claims abstract description 3
239000002253 acid Substances 0.000 claims abstract description 3
102000009310 vitamin D receptors Human genes 0.000 claims abstract description 3
108050000156 vitamin D receptors Proteins 0.000 claims abstract description 3
108090001005 Interleukin-6 Proteins 0.000 claims description 133
102000004889 Interleukin-6 Human genes 0.000 claims description 125
102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims description 92
101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims description 61
102000015694 estrogen receptors Human genes 0.000 claims description 48
239000000284 extract Substances 0.000 claims description 47
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 45
230000014509 gene expression Effects 0.000 claims description 45
229940100601 interleukin-6 Drugs 0.000 claims description 34
238000011282 treatment Methods 0.000 claims description 30
239000002158 endotoxin Substances 0.000 claims description 10
102000000589 Interleukin-1 Human genes 0.000 claims description 8
108010002352 Interleukin-1 Proteins 0.000 claims description 8
241000700605 Viruses Species 0.000 claims description 8
102000004890 Interleukin-8 Human genes 0.000 claims description 7
108090001007 Interleukin-8 Proteins 0.000 claims description 7
239000003446 ligand Substances 0.000 claims description 7
239000002644 phorbol ester Substances 0.000 claims description 7
102000003390 tumor necrosis factor Human genes 0.000 claims description 7
108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 6
102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 6
239000012636 effector Substances 0.000 claims description 6
230000003247 decreasing effect Effects 0.000 claims description 5
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 claims description 5
229940124597 therapeutic agent Drugs 0.000 claims description 5
102000003998 progesterone receptors Human genes 0.000 claims description 4
239000013598 vector Substances 0.000 claims description 4
108700008625 Reporter Genes Proteins 0.000 claims description 3
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
101800003838 Epidermal growth factor Proteins 0.000 claims description 2
102400001368 Epidermal growth factor Human genes 0.000 claims description 2
108010085012 Steroid Receptors Proteins 0.000 claims description 2
229940116977 epidermal growth factor Drugs 0.000 claims description 2
102000005969 steroid hormone receptors Human genes 0.000 claims description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
238000005259 measurement Methods 0.000 claims 2
102000011767 Acute-Phase Proteins Human genes 0.000 claims 1
108010062271 Acute-Phase Proteins Proteins 0.000 claims 1
241001514645 Agonis Species 0.000 claims 1
102000004877 Insulin Human genes 0.000 claims 1
108090001061 Insulin Proteins 0.000 claims 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 1
229940125396 insulin Drugs 0.000 claims 1
229940096397 interleukin-8 Drugs 0.000 claims 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical group C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 1
229940124606 potential therapeutic agent Drugs 0.000 claims 1
125000002678 retinoid group Chemical group 0.000 claims 1
239000005495 thyroid hormone Substances 0.000 claims 1
229940036555 thyroid hormone Drugs 0.000 claims 1
201000010099 disease Diseases 0.000 abstract description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
239000003795 chemical substances by application Substances 0.000 abstract description 8
108090000079 Glucocorticoid Receptors Proteins 0.000 abstract description 5
102000004217 thyroid hormone receptors Human genes 0.000 abstract description 3
108090000721 thyroid hormone receptors Proteins 0.000 abstract description 3
102000007474 Multiprotein Complexes Human genes 0.000 abstract description 2
108010085220 Multiprotein Complexes Proteins 0.000 abstract description 2
108010080146 androgen receptors Proteins 0.000 abstract description 2
102100032187 Androgen receptor Human genes 0.000 abstract 1
102100038595 Estrogen receptor Human genes 0.000 abstract 1
102100033417 Glucocorticoid receptor Human genes 0.000 abstract 1
102100025803 Progesterone receptor Human genes 0.000 abstract 1
150000004492 retinoid derivatives Chemical class 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 160
230000000694 effects Effects 0.000 description 60
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 56
229960005309 estradiol Drugs 0.000 description 47
229930182833 estradiol Natural products 0.000 description 45
229940011871 estrogen Drugs 0.000 description 39
239000000262 estrogen Substances 0.000 description 39
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 38
108010057466 NF-kappa B Proteins 0.000 description 35
230000006698 induction Effects 0.000 description 35
102000003945 NF-kappa B Human genes 0.000 description 33
101710123496 Spindolin Proteins 0.000 description 32
101710124574 Synaptotagmin-1 Proteins 0.000 description 26
102100035100 Transcription factor p65 Human genes 0.000 description 26
108020004414 DNA Proteins 0.000 description 24
230000004568 DNA-binding Effects 0.000 description 24
238000001994 activation Methods 0.000 description 24
239000000523 sample Substances 0.000 description 24
230000004913 activation Effects 0.000 description 23
239000012634 fragment Substances 0.000 description 23
230000033228 biological regulation Effects 0.000 description 22
238000002474 experimental method Methods 0.000 description 21
238000013518 transcription Methods 0.000 description 21
230000035897 transcription Effects 0.000 description 21
241000699666 Mus <mouse, genus> Species 0.000 description 20
102100023132 Transcription factor Jun Human genes 0.000 description 18
238000003556 assay Methods 0.000 description 18
230000001105 regulatory effect Effects 0.000 description 18
102000040945 Transcription factor Human genes 0.000 description 17
108091023040 Transcription factor Proteins 0.000 description 17
108091034117 Oligonucleotide Proteins 0.000 description 16
108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 16
102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 16
210000002536 stromal cell Anatomy 0.000 description 16
230000001404 mediated effect Effects 0.000 description 15
230000007246 mechanism Effects 0.000 description 14
230000002103 transcriptional effect Effects 0.000 description 14
108091027981 Response element Proteins 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
230000006870 function Effects 0.000 description 13
229940088597 hormone Drugs 0.000 description 13
238000000338 in vitro Methods 0.000 description 13
230000001629 suppression Effects 0.000 description 13
108010018242 Transcription Factor AP-1 Proteins 0.000 description 12
210000000963 osteoblast Anatomy 0.000 description 12
239000005089 Luciferase Substances 0.000 description 11
108060001084 Luciferase Proteins 0.000 description 11
239000005556 hormone Substances 0.000 description 11
239000002609 medium Substances 0.000 description 11
238000007069 methylation reaction Methods 0.000 description 11
102100026189 Beta-galactosidase Human genes 0.000 description 10
210000001185 bone marrow Anatomy 0.000 description 10
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 10
230000011987 methylation Effects 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 9
230000009918 complex formation Effects 0.000 description 9
239000003623 enhancer Substances 0.000 description 9
239000003112 inhibitor Substances 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
101710134031 CCAAT/enhancer-binding protein beta Proteins 0.000 description 8
102000003923 Protein Kinase C Human genes 0.000 description 8
108090000315 Protein Kinase C Proteins 0.000 description 8
210000000988 bone and bone Anatomy 0.000 description 8
239000000872 buffer Substances 0.000 description 8
238000012761 co-transfection Methods 0.000 description 8
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
150000003431 steroids Chemical class 0.000 description 8
101710087290 DNA primase small subunit Proteins 0.000 description 7
101710157837 Minor capsid protein p49 Proteins 0.000 description 7
102100029282 Serum response factor-binding protein 1 Human genes 0.000 description 7
108010090932 Vitellogenins Proteins 0.000 description 7
230000003262 anti-osteoporosis Effects 0.000 description 7
230000001419 dependent effect Effects 0.000 description 7
239000000499 gel Substances 0.000 description 7
229920006008 lipopolysaccharide Polymers 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
238000012360 testing method Methods 0.000 description 7
BDVFVCGFMNCYPV-NSHDSACASA-N 1-(5-isoquinolinesulfonyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1S(=O)(=O)C1=CC=CC2=CN=CC=C12 BDVFVCGFMNCYPV-NSHDSACASA-N 0.000 description 6
206010048998 Acute phase reaction Diseases 0.000 description 6
102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 description 6
102000039106 EBP family Human genes 0.000 description 6
108091065819 EBP family Proteins 0.000 description 6
101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
102100040296 TATA-box-binding protein Human genes 0.000 description 6
239000012190 activator Substances 0.000 description 6
230000004658 acute-phase response Effects 0.000 description 6
238000010367 cloning Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
210000002950 fibroblast Anatomy 0.000 description 6
238000011534 incubation Methods 0.000 description 6
230000003993 interaction Effects 0.000 description 6
230000037230 mobility Effects 0.000 description 6
230000035772 mutation Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
238000012546 transfer Methods 0.000 description 6
102000014914 Carrier Proteins Human genes 0.000 description 5
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 5
102000008379 I-kappa B Proteins Human genes 0.000 description 5
108010021699 I-kappa B Proteins Proteins 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
102000004380 Transcription factor RelB Human genes 0.000 description 5
108090000952 Transcription factor RelB Proteins 0.000 description 5
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
239000000556 agonist Substances 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
108091008324 binding proteins Proteins 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
230000004069 differentiation Effects 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 5
239000000833 heterodimer Substances 0.000 description 5
102000052611 human IL6 Human genes 0.000 description 5
210000005260 human cell Anatomy 0.000 description 5
230000017306 interleukin-6 production Effects 0.000 description 5
238000002955 isolation Methods 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
239000011701 zinc Substances 0.000 description 5
229910052725 zinc Inorganic materials 0.000 description 5
240000007124 Brassica oleracea Species 0.000 description 4
235000003899 Brassica oleracea var acephala Nutrition 0.000 description 4
235000012905 Brassica oleracea var viridis Nutrition 0.000 description 4
102000015280 CCAAT-Enhancer-Binding Protein-beta Human genes 0.000 description 4
102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 4
102000003676 Glucocorticoid Receptors Human genes 0.000 description 4
101000855520 Homo sapiens Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 4
101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 4
102000007999 Nuclear Proteins Human genes 0.000 description 4
108010089610 Nuclear Proteins Proteins 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
244000309464 bull Species 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
230000007423 decrease Effects 0.000 description 4
210000002919 epithelial cell Anatomy 0.000 description 4
238000000605 extraction Methods 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
238000010369 molecular cloning Methods 0.000 description 4
210000002997 osteoclast Anatomy 0.000 description 4
230000037361 pathway Effects 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
239000000047 product Substances 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
102000003702 retinoic acid receptors Human genes 0.000 description 4
108090000064 retinoic acid receptors Proteins 0.000 description 4
230000007017 scission Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000001890 transfection Methods 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
108090001067 Angiotensinogen Proteins 0.000 description 3
101150111062 C gene Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
101150074151 Ebp gene Proteins 0.000 description 3
108700039691 Genetic Promoter Regions Proteins 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
101000961071 Homo sapiens NF-kappa-B inhibitor alpha Proteins 0.000 description 3
101000979338 Homo sapiens Nuclear factor NF-kappa-B p100 subunit Proteins 0.000 description 3
BVVFOLSZMQVDKV-KXQIQQEYSA-N ICI-164384 Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](CCCCCCCCCCC(=O)N(C)CCCC)CC3=CC(O)=CC=C3[C@H]21 BVVFOLSZMQVDKV-KXQIQQEYSA-N 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
102100023059 Nuclear factor NF-kappa-B p100 subunit Human genes 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
102000043276 Oncogene Human genes 0.000 description 3
108010062618 Oncogene Proteins v-rel Proteins 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
240000007594 Oryza sativa Species 0.000 description 3
235000007164 Oryza sativa Nutrition 0.000 description 3
230000009471 action Effects 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000006037 cell lysis Effects 0.000 description 3
238000004581 coalescence Methods 0.000 description 3
239000002131 composite material Substances 0.000 description 3
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
229960003957 dexamethasone Drugs 0.000 description 3
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
238000006471 dimerization reaction Methods 0.000 description 3
230000003828 downregulation Effects 0.000 description 3
235000013399 edible fruits Nutrition 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
230000011132 hemopoiesis Effects 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
229960004452 methionine Drugs 0.000 description 3
239000000203 mixture Substances 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
238000009806 oophorectomy Methods 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
150000004633 phorbol derivatives Chemical class 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
208000001685 postmenopausal osteoporosis Diseases 0.000 description 3
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
235000009566 rice Nutrition 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
238000005406 washing Methods 0.000 description 3
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
108020005029 5' Flanking Region Proteins 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
241000271566 Aves Species 0.000 description 2
238000009010 Bradford assay Methods 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000052510 DNA-Binding Proteins Human genes 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102100032222 Emopamil-binding protein-like Human genes 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101001015930 Homo sapiens Emopamil-binding protein-like Proteins 0.000 description 2
101001086210 Homo sapiens Osteocalcin Proteins 0.000 description 2
108700005091 Immunoglobulin Genes Proteins 0.000 description 2
102000003815 Interleukin-11 Human genes 0.000 description 2
108090000177 Interleukin-11 Proteins 0.000 description 2
102000000646 Interleukin-3 Human genes 0.000 description 2
108010002386 Interleukin-3 Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
108010001267 Protein Subunits Proteins 0.000 description 2
102000002067 Protein Subunits Human genes 0.000 description 2
101000687509 Rattus norvegicus Prolactin Proteins 0.000 description 2
102000006467 TATA-Box Binding Protein Human genes 0.000 description 2
108010044281 TATA-Box Binding Protein Proteins 0.000 description 2
108050005223 Transcription factor Jun Proteins 0.000 description 2
241000269370 Xenopus <genus> Species 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
108010055905 alpha-Crystallin A Chain Proteins 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000001833 anti-estrogenic effect Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
210000002449 bone cell Anatomy 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
210000000172 cytosol Anatomy 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
150000002009 diols Chemical class 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000007877 drug screening Methods 0.000 description 2
230000002357 endometrial effect Effects 0.000 description 2
230000037149 energy metabolism Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000328 estrogen antagonist Substances 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
239000000710 homodimer Substances 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000000411 inducer Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
229940076264 interleukin-3 Drugs 0.000 description 2
229940043355 kinase inhibitor Drugs 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
230000001582 osteoblastic effect Effects 0.000 description 2
230000002188 osteogenic effect Effects 0.000 description 2
230000003642 osteotropic effect Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
235000011197 perejil Nutrition 0.000 description 2
229960003531 phenolsulfonphthalein Drugs 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
239000003757 phosphotransferase inhibitor Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000011546 protein dye Substances 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
108700021653 rel Genes Proteins 0.000 description 2
229930002330 retinoic acid Natural products 0.000 description 2
230000011664 signaling Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
108091006106 transcriptional activators Proteins 0.000 description 2
229960001727 tretinoin Drugs 0.000 description 2
235000019155 vitamin A Nutrition 0.000 description 2
239000011719 vitamin A Substances 0.000 description 2
235000019166 vitamin D Nutrition 0.000 description 2
239000011710 vitamin D Substances 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
CUJMXIQZWPZMNQ-XYYGWQPLSA-N 13,14-dihydro-15-oxo-prostaglandin E2 Chemical compound CCCCCC(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CUJMXIQZWPZMNQ-XYYGWQPLSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
102100038910 Alpha-enolase Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
102100034613 Annexin A2 Human genes 0.000 description 1
108090000668 Annexin A2 Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101000850966 Cavia porcellus Eosinophil granule major basic protein 1 Proteins 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
108700020911 DNA-Binding Proteins Proteins 0.000 description 1
101710096438 DNA-binding protein Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108090000331 Firefly luciferases Proteins 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
101000979343 Gallus gallus Nuclear factor NF-kappa-B p100 subunit Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
240000008892 Helianthus tuberosus Species 0.000 description 1
235000003230 Helianthus tuberosus Nutrition 0.000 description 1
101000882335 Homo sapiens Alpha-enolase Proteins 0.000 description 1
101000945963 Homo sapiens CCAAT/enhancer-binding protein beta Proteins 0.000 description 1
101000736088 Homo sapiens PC4 and SFRS1-interacting protein Proteins 0.000 description 1
101000714470 Homo sapiens Synaptotagmin-1 Proteins 0.000 description 1
101000723920 Homo sapiens Zinc finger protein 40 Proteins 0.000 description 1
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
241001562081 Ikeda Species 0.000 description 1
102000004125 Interleukin-1alpha Human genes 0.000 description 1
108010082786 Interleukin-1alpha Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
241000406668 Loxodonta cyclotis Species 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
108700005089 MHC Class I Genes Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
101100524295 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) relB3 gene Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101000882586 Mus musculus Estrogen receptor Proteins 0.000 description 1
101001002507 Mus musculus Immunoglobulin-binding protein 1 Proteins 0.000 description 1
101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
101000714466 Mus musculus Synaptotagmin-1 Proteins 0.000 description 1
BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
-1 NF-IL6 Proteins 0.000 description 1
108010006401 NF-kappa B p50 Subunit Proteins 0.000 description 1
102000005395 NF-kappa B p50 Subunit Human genes 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
241000315040 Omura Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000208317 Petroselinum Species 0.000 description 1
240000009164 Petroselinum crispum Species 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000283080 Proboscidea <mammal> Species 0.000 description 1
229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
101001062854 Rattus norvegicus Fatty acid-binding protein 5 Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
241000220317 Rosa Species 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
241001611093 Stimula Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108700026226 TATA Box Proteins 0.000 description 1
241000656145 Thyrsites atun Species 0.000 description 1
102000005747 Transcription Factor RelA Human genes 0.000 description 1
108010031154 Transcription Factor RelA Proteins 0.000 description 1
102000006290 Transcription Factor TFIID Human genes 0.000 description 1
108010083268 Transcription Factor TFIID Proteins 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
101710195626 Transcriptional activator protein Proteins 0.000 description 1
239000007997 Tricine buffer Substances 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
101710159283 Vitellogenin-A2 Proteins 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
102000001307 androgen receptors Human genes 0.000 description 1
108010032316 angiotensinogen gene-inducible enhancer-protein 1 Proteins 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003011 anion exchange membrane Substances 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000010455 autoregulation Effects 0.000 description 1
230000006420 basal activation Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000012148 binding buffer Substances 0.000 description 1
210000004271 bone marrow stromal cell Anatomy 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
230000034127 bone morphogenesis Effects 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
239000005516 coenzyme A Substances 0.000 description 1
229940093530 coenzyme a Drugs 0.000 description 1
229940052810 complex b Drugs 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007123 defense Effects 0.000 description 1
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000003370 dye binding method Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000005188 flotation Methods 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
208000024386 fungal infectious disease Diseases 0.000 description 1
238000003209 gene knockout Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000005639 glycero group Chemical group 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000002607 hemopoietic effect Effects 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
230000007236 host immunity Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000021995 interleukin-8 production Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
230000000921 morphogenic effect Effects 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000004031 neuronal differentiation Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
102000006255 nuclear receptors Human genes 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
210000005009 osteogenic cell Anatomy 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000012466 permeate Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
108010031345 placental alkaline phosphatase Proteins 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
239000000007 protein synthesis inhibitor Substances 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
238000011158 quantitative evaluation Methods 0.000 description 1
108010023714 recombinant human bone morphogenetic protein-2 Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000025512 regulation of interleukin-6 production Effects 0.000 description 1
101150023313 relB gene Proteins 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000036301 sexual development Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
229960003885 sodium benzoate Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
235000018553 tannin Nutrition 0.000 description 1
229920001864 tannin Polymers 0.000 description 1
239000001648 tannin Substances 0.000 description 1
150000003536 tetrazoles Chemical group 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
230000037426 transcriptional repression Effects 0.000 description 1
108091006107 transcriptional repressors Proteins 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000000717 tumor promoter Substances 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
239000004474 valine Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP7529916A 1994-05-18 1995-05-15 サイトカインモジュレーターのスクリーニング Pending JPH10500485A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US24547094A	1994-05-18	1994-05-18
US08/245,470		1994-05-18
PCT/US1995/006524 WO1995031722A1 (fr)	1994-05-18	1995-05-15	Triage pour la detection de modulateurs des cytokines

Publications (1)

Publication Number	Publication Date
JPH10500485A true JPH10500485A (ja)	1998-01-13

Family

ID=22926786

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP7529916A Pending JPH10500485A (ja)	1994-05-18	1995-05-15	サイトカインモジュレーターのスクリーニング

Country Status (5)

Country	Link
EP (1)	EP0765475A1 (fr)
JP (1)	JPH10500485A (fr)
AU (1)	AU2646295A (fr)
CA (1)	CA2190275A1 (fr)
WO (1)	WO1995031722A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4436352A1 (de) *	1994-10-12	1996-04-18	Kay Brune	Verfahren zur diagnostischen Beurteilung und Verlaufskontrolle sowie Arzneimittel zur Therapie von Schockzuständen beim Menschen
GB9424497D0 (en) *	1994-12-05	1995-01-25	Karobio Ab	Reporter cell line
GB9608133D0 (en) *	1996-04-19	1996-06-26	Gemini International Holdings	Diagnostic method and apparatus
US6692928B1 (en)	1996-07-19	2004-02-17	New England Medical Center Hospitals, Inc.	Methods for identifying cardiovascular agents
US5728534A (en)	1996-07-19	1998-03-17	New England Medical Center Hospitals, Inc.	Methods for identifying cardiovascular therapeutic agents
DE69635462T2 (de) *	1996-09-27	2006-08-17	The Board of Regents, The University of Texas System, Austin	Screeningmethoden für glucocorticoidrezeptor-bindende substanzen unter verwendung von trypterygium wilfordii zubereitungen
EP0987552A3 (fr) *	1998-08-31	2000-06-07	Pfizer Products Inc.	Protéines de liaison pour diarylsulfonylurée
CN1341213A (zh) *	1999-02-18	2002-03-20	中外制药株式会社	筛选具有维生素d受体亲和性的化合物的方法
US6764826B2 (en)	2000-06-08	2004-07-20	Board Of Regents, The University Of Texas System	Inhibitors of C-reactive protein induced inflammation
HRP20040102A2 (en) *	2001-07-09	2004-10-31	Combinatorx	Combinations for the treatment of inflammatory disorders
AU2003219136A1 (en) *	2002-02-25	2003-09-09	Akzo Nobel N.V.	Estrogen receptor interaction with a transcription factor
WO2005030994A1 (fr)	2003-09-26	2005-04-07	International Institute Of Molecular And Cell Biology In Warsaw	Cellules et procedes utilises dans la caracterisation de l'activite immunotoxique de substances xenobiotiques
US8519158B2 (en)	2004-03-12	2013-08-27	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
EP2511382A1 (fr) *	2011-04-14	2012-10-17	Université de Strasbourg	Procédé pour identifier de nouvelles molécules anti-inflammatoires avec une transrepression directe réduite de gènes induite par glucocorticoïdes
WO2020214834A1 (fr)	2019-04-19	2020-10-22	Ligand Pharmaceuticals Inc.	Formes cristallines et procédés de production de formes cristallines d'un composé

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992007072A1 (fr) *	1990-10-10	1992-04-30	La Jolla Cancer Research Foundation	Procede d'inhibition de transcription utilisant des recepteurs nucleaires

1995
- 1995-05-15 CA CA002190275A patent/CA2190275A1/fr not_active Abandoned
- 1995-05-15 JP JP7529916A patent/JPH10500485A/ja active Pending
- 1995-05-15 EP EP95921363A patent/EP0765475A1/fr not_active Withdrawn
- 1995-05-15 AU AU26462/95A patent/AU2646295A/en not_active Abandoned
- 1995-05-15 WO PCT/US1995/006524 patent/WO1995031722A1/fr not_active Ceased

Also Published As

Publication number	Publication date
WO1995031722A1 (fr)	1995-11-23
EP0765475A1 (fr)	1997-04-02
CA2190275A1 (fr)	1995-11-23
AU2646295A (en)	1995-12-05

Publication	Publication Date	Title
Liu et al.	2004	Synergistic activation of interleukin-12 p35 gene transcription by interferon regulatory factor-1 and interferon consensus sequence-binding protein
Maruyama et al.	2008	Molecular and cellular mechanisms for differentiation and regeneration of the uterine endometrium
Bodor et al.	1996	cAMP inducibility of transcriptional repressor ICER in developing and mature human T lymphocytes.
Srivastava et al.	1998	Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1.
Edbrooke et al.	1989	Identification of cis-acting sequences responsible for phorbol ester induction of human serum amyloid A gene expression via a nuclear factor κB-like transcription factor
Zemel et al.	1995	Agouti regulation of intracellular calcium: role in the insulin resistance of viable yellow mice.
Poncelet et al.	1999	The transforming growth factor-βbgr/SMAD signaling pathway is present and functional in human mesangial cells
Scott et al.	1992	Molecular cloning of the bovine prolactin receptor and distribution of prolactin and growth hormone receptor transcripts in fetal and utero-placental tissues
JPH10500485A (ja)	1998-01-13	サイトカインモジュレーターのスクリーニング
Wissink et al.	1997	NF-κB/Rel family members regulating the ICAM-1 promoter in monocytic THP-1 cells
Litterst et al.	2002	An LXXLL motif in the transactivation domain of STAT6 mediates recruitment of NCoA-1/SRC-1
Díaz-Hernández et al.	2015	Exogenous estradiol alters gonadal growth and timing of temperature sex determination in gonads of sea turtle
Wang et al.	2004	Groucho homologue Grg5 interacts with the transcription factor Runx2–Cbfa1 and modulates its activity during postnatal growth in mice
McKinsey et al.	2000	Transcription factor NF-κB regulates inducible CD83 gene expression in activated T lymphocytes
Felli et al.	1991	Retinoic acid-induced down-regulation of the interleukin-2 promoter via cis-regulatory sequences containing an octamer motif
Mouillet et al.	2004	p300 regulates the synergy of steroidogenic factor-1 and early growth response-1 in activating luteinizing hormone-β subunit gene
Alemany et al.	1990	Transcriptional stimulation of the delta 1-crystallin gene by insulin-like growth factor I and insulin requires DNA cis elements in chicken.
Walker et al.	1998	Inducible cAMP early repressor ICER down-regulation of CREB gene expression in Sertoli cells
JP2002525602A (ja)	2002-08-13	体重を調節する化合物を同定するための標的としてのｇｐｒ１０
US5928881A (en)	1999-07-27	Method of identifying agonists and antagonist for CC-CKR5 receptor
Khromykh et al.	2007	Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells
Merola et al.	1996	The κB enhancer of the human interleukin-6 promoter is necessary and sufficient to confer an IL-1β and TNF-α response in transfected human cell lines: requirement for members of the C/EBP family for activity
Saisanit et al.	1997	Regulation of the pro-B-cell-specific enhancer of the Id1 gene involves the C/EBP family of proteins
JP2002506004A (ja)	2002-02-26	レプチン活性を調節するための方法および組成物
Miyazawa et al.	1999	IL-6 synthesis by rheumatoid synoviocytes is autonomously upregulated at the transcriptional level